Chronic Back Pain Pipeline Review, 2024

Chronic back pain is pain that persists after a surgery or injury. The common causes of the chronic back pain include arthritis of the spine, spinal stenosis, disc problems, myofascial pain syndrome, and others. The symptoms commonly seen are acute lower back pain. The pain might spread (radiate) to the buttocks, thighs or knees. Depending on the type of the back pain the treatments are recommended and some of the common treatments recommended are Over-the-counter (OTC) pain reliever, muscle relaxants, topical pain relievers, narcotics, and others. According to a research publication by NCBI, in the United States, the lifetime prevalence of back pain is approximately 80%, with a one-year prevalence rate of 15% to 20%.

Current treatment for chronic back pain includes non-surgical treatment with limited rest, pain medication, and a supervised therapy program. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen are prescribed for chronic back pain.

Pharmaceutical companies have focussed on studying and developing new methods for the treatment of chronic back pain. For instance; PF-06372865, which is being studied by Pfizer Inc., is currently in phase-2 clinical trials for the study the treatment of the chronic lower back pain.

At present, more than 50% of the pipeline candidates for chronic back pain are in the phase 2 and phase 3 stages combined. Pharmaceutical companies have sponsored most of the studies.

Report Description

The report on ‘Chronic Back Pain – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for chronic back pain. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for chronic back pain.

The report on ‘Chronic Back Pain – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for chronic back pain


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for chronic back pain


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary